Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07606430

Comparison of a Short Modified Metal Stent Versus Plastic Stent as a Bridge to Surgery in Pancreatic Cancer With Malignant Biliary Obstruction

This study is a multicenter, randomized clinical trial designed to compare the effectiveness and safety of a modified 8-mm fully covered self-expandable metal stent (FCSEMS) with a conventional plastic stent for preoperative biliary drainage in patients with pancreatic cancer and malignant biliary obstruction.

In patients who require biliary drainage before surgery, stent placement is commonly performed using endoscopic retrograde cholangiopancreatography (ERCP). However, the optimal stent type remains uncertain.

Participants will be randomly assigned to receive either the modified FCSEMS or a plastic stent. The primary objective is to evaluate the rate of stent-related complications requiring reintervention before surgery. Secondary outcomes include stent patency, adverse events, and surgical outcomes.

The results of this study are expected to help determine the most appropriate stent strategy for patients undergoing surgery for pancreatic cancer.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, and many patients present with malignant biliary obstruction at the time of diagnosis. Preoperative biliary drainage is frequently required in patients undergoing neoadjuvant chemotherapy or delayed surgery to relieve jaundice and prevent complications such as cholangitis.

Endoscopic retrograde cholangiopancreatography (ERCP) with stent placement is the standard approach for biliary drainage. Plastic stents (PS) are widely used due to their low cost and ease of removal; however, they are associated with a relatively short patency and frequent occlusion, often necessitating repeated interventions. Fully covered self-expandable metal stents (FCSEMS) have demonstrated longer patency, but concerns remain regarding adverse events and potential impact on subsequent surgical procedures.

A modified non-flared 8-mm diameter FCSEMS has been developed to reduce complications while maintaining adequate patency. Its design includes a dumbbell-shaped structure with a narrower central portion to prevent migration, a fully covered membrane to reduce tissue ingrowth, and a retrieval lasso to facilitate removal. This design may offer advantages over both conventional FCSEMS and plastic stents in the preoperative setting.

This study is a prospective, multicenter, open-label, randomized controlled trial designed to compare a modified 8-mm FCSEMS with a plastic stent for preoperative biliary drainage in patients with pancreatic cancer and malignant biliary obstruction. Eligible patients will be randomly assigned in a 1:1 ratio to receive either the modified FCSEMS or a plastic stent.

The primary endpoint is the stent-related non-event rate at the time of surgery, defined as the proportion of patients who do not require reintervention due to stent-related complications before surgery. Secondary endpoints include the incidence of recurrent biliary obstruction, time to recurrent biliary obstruction, stent-related adverse events, technical success, surgical outcomes, and overall survival.

All procedures will be performed using standard ERCP techniques by experienced endoscopists. Patients will be followed until surgery and throughout the postoperative period to assess clinical outcomes.

The findings of this study are expected to provide evidence to guide optimal stent selection for preoperative biliary drainage in patients with pancreatic cancer, particularly in the context of neoadjuvant treatment strategies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Patients with resectable, borderline resectable, or locally advanced pancreatic cancer with distal malignant biliary obstruction requiring endoscopic biliary drainage
  • Biliary stricture located ≥ 2 cm below the hepatic hilum
  • Serum bilirubin ≥ 3 mg/dL
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Ability to provide written informed consent

Exclusion criteria

  • Presence of distant metastasis
  • Prior biliary stent placement for biliary obstruction
  • Requirement for duodenal stent placement due to gastric outlet obstruction
  • Estimated life expectancy < 3 months
  • Inability to undergo ERCP
  • Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study outcomes

Treatment and study plan

Modified 8-mm Fully Covered Self-Expandable Metal Stent

Device

A modified non-flared 8-mm fully covered self-expandable metal stent designed for preoperative biliary drainage. The stent features a dumbbell-shaped structure with a narrower central portion to reduce migration, a fully covered membrane to prevent tissue ingrowth, and a retrieval lasso to facilitate removal. It is deployed via ERCP across the malignant biliary stricture.

Other names: M-FCSEMS

Plastic Stent

Device

A conventional 8.5-Fr plastic biliary stent used for preoperative biliary drainage. The stent is placed via ERCP across the malignant biliary stricture and represents the standard treatment option, although it is associated with shorter patency and a higher risk of occlusion compared to metal stents.

Other names: PS

Primary outcomes

  1. Stent-Related Non-Event Rate at Surgery

    Time frame: From stent placement to the time of surgery

    The proportion of patients who do not require reintervention due to stent-related complications from stent placement until the time of surgery.

Secondary outcomes

  1. Recurrent Biliary Obstruction Rate

    Time frame: From stent placement to RBO, assessed up to 24 months

    The proportion of patients who develop recurrent biliary obstruction requiring reintervention

  2. Time to Recurrent Biliary Obstruction

    Time frame: From stent placement to first RBO, assessed up to 24 months

    Time from stent placement to the occurrence of recurrent biliary obstruction

  3. Stent-Related Adverse Events

    Time frame: Within 30 days after procedure

    Incidence of adverse events related to stent placement, including pancreatitis, cholangitis, cholecystitis, bleeding, perforation, or stent migration

  4. Technical Success Rate

    Time frame: During the index procedure

    Successful placement of the stent across the target biliary stricture in the intended position

  5. Surgery Completion Rate

    Time frame: Up to surgery

    The proportion of patients who undergo planned surgical resection after biliary drainage

  6. Overall Survival

    Time frame: From procedure to death from any cause, assessed up to 24 months

    Time from stent placement to death from any cause

Study contacts

Contact information is provided by the study sponsor or research team.

Il Sang Shin, Assistant Professor

CONTACT

[email protected]

+82-10-4658-8794

Sponsors and collaborators

Lead sponsor

Soonchunhyang University Hospital

Other

Collaborators

  • Asan Medical Center
  • Samsung Medical Center

Registry information

Official study title

Multicenter Randomized Trial of a Short Modified 8-mm-diameter Fully Covered Metal Stent Versus Plastic Stent as a Bridge to Surgery in Pancreatic Cancer With Malignant Biliary Obstruction

Acronym: BRIDGE-8

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
May 26, 2026
Registry last updated
May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.